References
- Dormandy J., Mahir M., Ascady G. et al. Fate of the patient with chronic leg ischaemia. J Cardiovasc Surgery, 1989, 30: 50-7.
- Clement D. L., Boccalon H., Dormandy J. et al. The CoCaLis document. A clinical approach to the Management of the patient with Coronary (Co) and/or Carotid (Ca) Artery Disease who presents with Leg Ischaemia (Lis). Int Angiology, 2000, 19: 97-125.
- Clement D. L., Van Maele G. O., De Pue N. Critical evaluation of venous occlusion plethysmography in the diagnosis of occlusive arterial diseases in the lower limbs. Int Angiology, 1985, 4: 69-74.
- Hiatt Wr, Regensteiner J. G., Hargarten M. E., Wolfel E. E., Brass E. P. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation, 1990, 81: 602-9.
- Antiplatelet Trialists’ Collaboration: Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ, 1988, 296: 320-31.
- Hess M., Mietaschk A., Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet, 1985, 11: 415-8.
- CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348: 1329-39.
- Scottish Intercollegiate Guidelines Network. Drug Therapy for Peripheral Vascular Disease. Eds. Sign Publications, 1998, 27: 1-23.
- Lindgarde F., Jelnes R., Bjorkman H. et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation, 1989, 80: 1549-56.
- Truebestein G., Balzer K., Bisler H. et al. Buflomedil in arterial occlusive disease: Results of a controlled multicenter study. Angiology, 1984, 35 (8): 500-5.
- Diamantopoulos E. J., Raptis S. A., Christodoulou-Peters M., Moulopoulos S. D. Experience with buflomedil in peripheral arterial occlusive disease. Report BUG-021.81. Abbott Laboratories. In: International Frankfurt Symposium, January, 1989, 80-4.
- Adhoute G., Bacourt F., Barral M. et al. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg. Angiology, 1986, 37: 160-7.
- Adhoute G., Andreassian B., Boccalon H. et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: Results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol, 1990, 16: S75-S80.
- Kreissmann A., Neiss A. Clinical effectiveness of naftidrofuryl in intermittent claudication. Vasa Suppl, 1988, 24: 27-32.
- Moody A. P., Al-Khaffaf H. S., Lehert P., Haris P. L., Charlesworth D. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol, 1994, 23: S44-S47.
- Brevetti G., Perna S., Sabba C. et al. Superiority of L-propionyl carnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, doubleblind, cross-over study. Eur Heart J, 1992, 13: 251-5.
- Okuda Y., Kimura Y., Yamashita K. Cilostazol. Cardiovasc Drug Rev, 1993, 11: 451-65.
- Liard F., Benichou A. C., Gamand S., Lehert Ph. The effects of Naftidrofuryl on Quality of Life Dis Manage Health Outcome, 1997, 2: 71-8.